Abstract: This invention relates to a novel fused tricyclic heterocycle of the formula (Ia, Ib) and its use for the treatment of hyper-proliferative disorders

Abstract: This invention relates to a compound of Formula (I) and its use in treating hyper-proliferative disorders.

Abstract: This invention relates to a compound of Formula (I) wherein Y is CH or N; Ar1 is phenyl or pyridyl each optionally substituted with 1 or 2 substituents each selected independently from (C1-C3)alkoxy halo, OH, CF3, CN, NO2 and (C1-C3)alkyl, said alkyl being optionally substituted with CF3; Ar2 is phenyl or pyridyl each option-ally substituted with 1 or 2 substituents each independently selected from halo, OH, CN, NO2, CF3, (C1-C6)alkoxy, NR1R1, S(O)2R2, C(O)R3, and (C1-C6)alkyl optionally substituted with R4, and its use in treating hyper-proliferative disorders.

Abstract: This invention relates to a compound of Formula I (I) and its use in treating hyper-proliferative disorders and diseases associated with angiogenesis.

Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.

Abstract: This invention relates to a novel fused tricyclic heterocycle of the formula (Ia, Ib) and its use for the treatment of hyper-proliferative disorders.

Abstract: This invention relates to novel benzofuran and benzothiophene derivatives of the general table formula and their use for the treatment of hyper-proliferative disorders.

Abstract: Disclosed are pyrazolyl derivative compounds or purified stereoisomers or stereoisomer mixtures of said compounds and their salts or prodrug forms thereof which have structural formula (I) or (II): wherein the variables R, R1, R2, R5 and R6 are as defined in the specification. The compounds are useful for the treatment or prevention of diseases and/or behaviors involving the 5-HT2C receptor.

Abstract: Disclosed are 4-sulfide/sulfoxide/sulfonyl-1H-pyrazolyl derivative compounds of formulas (I) or (II): wherein the variables n, R, R1, R2, R3, R3?, R4, R4?, R5 and R6 are as defined in the specification. The compounds are useful for the treatment or prevention of diseases and/or behaviors involving the 5-HT2C receptor.

Abstract: The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.

Abstract: The invention provides novel thiazoles bearing 3-pyridyl or 4-isoquinilinyl substituents, and pharmaceutical compositions thereof. The invention also provides methods of using compounds of the invention and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17a-hydroxylase-C17,20 enzyme. The invention further provides methods for treating cancer in a subject, comprising administering to the subject a compound of the invention or a pharmaceutical composition thereof. The cancer can be, e.g., prostate cancer or breast cancer.

Abstract: The anthracene-spiro-pyrrolidines according to the invention are prepared by reacting either anthracene-spiro-furans or unsubstituted anthracene-spiropyrrolidines with appropriately substituted amines or by reacting unsubstituted anthracene derivatives with appropriately substituted methylenepyrrolidines. The substances can be used as active agents in medicaments, in particular for the production of immunomodulating medicaments.

Abstract: N,N-Disubstitued piperazines are prepared by reacting either the appropriately substituted furans or the N-unsubstituted pyrrolidines with aminoalkylpiperazines. The substances according to the invention can be employed as active agents in medicaments, in particular for the production of immunomodulators.

Abstract: Substituted pyrroloanthracenes are prepared by reacting either furanoanthracenes or N-unsubstituted pyrroloanthracenes with appropriately substituted alkylamines. The compounds can be employed as active ingredients in medicaments, in particular as immunomodulators.

Abstract: The piperazine-substituted pyrroloanthracenes are prepared by reacting either furanoanthracenes with piperazinalkylamines or reacting unsubstituted pyrroloanthracenes first with dihalogenoalkyl compounds and then with appropriately substituted piperazines or by reacting furan derivatives first with piperazinalkylamines and then condensing with anthracenes. The new compounds can be employed as active ingredients in medicaments, in particular in immunomodulators.